信--使用 ASCO 价值框架指南和 NCCN 证据块更正恩扎卢胺的净健康获益计算。
Letter--Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks.
机构信息
1 Senior Director, Health Economics and Outcomes Research-Oncology Astellas Pharma.
2 Senior Medical Director, Oncology Astellas Pharma.
出版信息
J Manag Care Spec Pharm. 2017 Nov;23(11):1202. doi: 10.18553/jmcp.2017.23.11.1202.
Abstract
This research was funded by Astellas Pharma and Medivation, which was acquired by Pfizer in 2016. Astellas Pharma and Medivation are the co-developers of enzalutamide. Flanders, Brown, Massoudi, and Schultz are employees of Astellas Pharma. Ramaswamy is an employee of Pfizer and holds stock in Johnson & Johnson. Flanders holds stock in Johnson & Johnson, AbbVie, and Abbott Labs.
摘要
这项研究由安斯泰来制药（Astellas Pharma）和辉瑞（Pfizer）旗下的 Medivation 共同资助，后者于 2016 年被辉瑞收购。安斯泰来制药和辉瑞旗下的 Medivation 是恩杂鲁胺的共同开发者。范德斯（Flanders）、布朗（Brown）、马苏德（Massoudi）和舒尔茨（Schultz）是安斯泰来制药的员工。拉马萨米（Ramaswamy）是辉瑞的员工，并持有强生（Johnson & Johnson）的股票。范德斯持有强生、艾伯维（AbbVie）和雅培实验室（Abbott Labs）的股票。
相似文献
1
Letter--Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks.信--使用 ASCO 价值框架指南和 NCCN 证据块更正恩扎卢胺的净健康获益计算。
J Manag Care Spec Pharm. 2017 Nov;23(11):1202. doi: 10.18553/jmcp.2017.23.11.1202.
2
Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.恩杂鲁胺治疗去势抵抗性前列腺癌的预算影响。
J Manag Care Spec Pharm. 2020 Apr;26(4):538-549. doi: 10.18553/jmcp.2020.19329. Epub 2020 Feb 5.
3
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.LBA02-09：EMBARK 研究：恩扎卢胺或安慰剂联合醋酸亮丙瑞林与恩扎卢胺单药治疗高危生化复发前列腺癌的 3 期随机研究。
J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2.
4
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.恩扎卢胺对比比卡鲁胺用于转移性前列腺癌患者的疗效和安全性（TERRAIN）：一项随机、双盲、2 期研究。
Lancet Oncol. 2016 Feb;17(2):153-163. doi: 10.1016/S1470-2045(15)00518-5. Epub 2016 Jan 14.
5
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移性患者的疗效。
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
6
Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.雄激素剥夺治疗抵抗性前列腺癌患者使用皮质类固醇的医疗资源利用和成本：一项行政索赔分析。
J Manag Care Spec Pharm. 2019 Aug;25(8):889-897. doi: 10.18553/jmcp.2019.19109. Epub 2019 Jun 7.
7
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.醋酸阿比特龙或恩杂鲁胺治疗的前列腺癌患者的治疗持续时间。
J Manag Care Spec Pharm. 2017 Feb;23(2):225-235. doi: 10.18553/jmcp.2016.16233. Epub 2016 Dec 7.
8
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移患者。
Expert Opin Pharmacother. 2020 Dec;21(17):2091-2099. doi: 10.1080/14656566.2020.1803281. Epub 2020 Aug 12.
9
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.恩扎卢胺与非转移性去势抵抗性前列腺癌的生存。
N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29.
10
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.恩杂鲁胺用于在化疗前治疗转移性激素复发前列腺癌：© 英国国家卫生与临床优化研究所（2016年）恩杂鲁胺用于在化疗前治疗转移性激素复发前列腺癌。
BJU Int. 2017 Aug;120(2):168-184. doi: 10.1111/bju.13936.
本文引用的文献
1
Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.患者-提供者互动的价值框架：ASCO 价值框架与 NCCN 证据块在肿瘤学中确定价值的比较。
J Manag Care Spec Pharm. 2017 Jun;23(6-a Suppl):S13-S20. doi: 10.18553/jmcp.2017.23.6-a.s13.
2
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.更新美国临床肿瘤学会价值框架：针对收到的评论进行的修订与思考
J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.
3
Enzalutamide in metastatic prostate cancer before chemotherapy.恩杂鲁胺治疗化疗前转移性前列腺癌。
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
4
Increased survival with enzalutamide in prostate cancer after chemotherapy.恩杂鲁胺可提高化疗后前列腺癌患者的生存率。
N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.
Zotero 插件